Climb Bio (CLYM) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 503.3% versus a loss of 35.5%. Over five years, CLYM leads with a -32.7% price change compared with -78.1% for PHAT. Climb Bio is the larger company by market cap ($623.8 million vs $576.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | PHAT |
|---|---|---|
| Share price | $10.86 | $7.13 |
| Market cap | $623.76M | $576.82M |
| 1-day change | +1.40% | +4.70% |
| YTD return | +171.50% | -57.02% |
| 1-year return | +503.33% | -35.48% |
| 5-year return | -32.71% | -78.07% |
| Forward P/E | — | 6.62 |
| EPS (TTM) | $-0.82 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $18.31 |
| 52-week low | $1.64 | $6.52 |
| Distance from 52-week high | -40.75% | -61.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +153.87% | +186.82% |
| Average volume | 1.37M | 1.38M |
| Shares outstanding | 57.44M | 80.90M |
| Employees | 28 | 371 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed PHAT by 538.8 percentage points over the past year.
- The two companies sit in different sectors: Climb Bio in Health Care and Phathom Pharmaceuticals in Healthcare.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Healthcare · Biotechnology · 371 employees
CLYM vs PHAT FAQ
Which is bigger, Climb Bio or Phathom Pharmaceuticals?
Climb Bio (CLYM) is larger, with a market capitalization of $623.76M compared with $576.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, CLYM or PHAT?
CLYM returned +503.33% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Phathom Pharmaceuticals in the same industry?
No. Climb Bio is in the Health Care sector, while Phathom Pharmaceuticals is in Healthcare.